CRON Cronos Group Inc.
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1656472 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY55.8%
TTM net income YoY60.2%
TTM EPS YoY60.0%
Revenue 3-yr CAGR34.2%
Net income 3-yr CAGR—
Margins
Gross margin46.6%
Operating margin3.4%
Net margin28.0%
FCF margin31.7%
EBITDA margin7.4%
Returns
ROE5.4%
ROA4.9%
ROIC (approx.)1.5%
Asset turnover0.17x
Leverage & solvency
Liabilities / assets6.1%
Debt / equity0.00x
Current ratio12.71x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.40x
Accruals ratio-2.0%
Payout ratio—
Capex / revenue7.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $63.45M | $53.01M | $45.21M | $44.53M | $36.34M | $33.45M | $32.26M | $30.30M |
| Gross profit | $32.28M | $28.45M | $19.15M | $16.19M | $18.33M | $14.50M | $13.73M | $10.81M |
| R&D expense | $1.34M | $1.22M | $1.41M | $1.38M | $1.34M | $929,000 | $793,000 | $1.03M |
| SG&A expense | $12.00M | $10.80M | $11.74M | $12.90M | $9.25M | $10.54M | $9.31M | $12.08M |
| Operating income | $9.03M | $7.40M | -$1.83M | -$7.50M | -$503,000 | -$5.32M | -$4.07M | -$11.37M |
| Pretax income | $18.72M | $35.71M | $18.14M | -$12.39M | $27.00M | -$39.01M | $7.27M | $45.95M |
| Income tax | $898,000 | $51,000 | $2.43M | -$11.89M | -$1.32M | -$525,000 | -$455,000 | $2.00M |
| Net income | $13.80M | $32.09M | $13.75M | -$1.82M | $25.96M | -$39.71M | $6.12M | $43.73M |
| EBITDA | $9.38M | $7.78M | $1.89M | -$3.84M | -$149,000 | -$4.46M | -$1.23M | -$8.84M |
| EPS (basic) | 0.04 | 0.09 | 0.04 | — | 0.07 | -0.10 | 0.02 | — |
| EPS (diluted) | 0.04 | 0.09 | 0.04 | — | 0.07 | -0.10 | 0.02 | — |
| Weighted avg. shares (diluted) | 370.72M | 375.06M | 381.80M | — | 384.99M | 385.31M | 386.96M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $411.19M | $467.02M | $821.86M | $791.79M | $784.17M | $794.42M | $797.82M | $858.80M |
| Short-term investments | $329.98M | $330.00M | $0 | $40.00M | $40.00M | $40.00M | $40.00M | $0 |
| Receivables | $44.23M | $36.72M | $32.96M | $34.10M | $27.09M | $26.62M | $18.71M | $15.46M |
| Inventory | $54.52M | $52.70M | $48.68M | $46.75M | $48.17M | $42.14M | $34.60M | $33.15M |
| Current assets | $859.31M | $912.03M | $927.88M | $944.09M | $922.15M | $927.15M | $918.58M | $936.11M |
| PP&E, net | $144.05M | $141.54M | $142.10M | $145.87M | $145.54M | $150.24M | $139.19M | $133.19M |
| Goodwill | $63.98M | $64.15M | $65.44M | $66.48M | $65.41M | $66.92M | $63.27M | $63.45M |
| Intangibles | $7.65M | $8.05M | $8.55M | $8.89M | $9.83M | $10.56M | $10.62M | $11.26M |
| Total assets | $1.20B | $1.18B | $1.17B | $1.20B | $1.18B | $1.18B | $1.15B | $1.17B |
| Current liabilities | $67.59M | $56.36M | $42.42M | $48.19M | $41.07M | $37.61M | $33.05M | $49.70M |
| Total liabilities | $73.40M | $62.41M | $48.30M | $54.18M | $46.36M | $45.02M | $39.06M | $55.33M |
| Shareholders' equity | $1.07B | $1.07B | $1.07B | $1.09B | $1.08B | $1.08B | $1.07B | $1.06B |
| Shares outstanding | 367.53M | 370.73M | 376.26M | 381.59M | 382.89M | 383.81M | 385.41M | 382.53M |
| Cash flow statement | ||||||||
| Operating cash flow | $34.34M | $24.01M | $10.90M | $11.84M | $13.31M | $2.82M | -$2.10M | $7.72M |
| Capital expenditure | $9.95M | $1.74M | $1.88M | $2.14M | $4.48M | $3.84M | $15.26M | $3.54M |
| Free cash flow | $24.39M | $22.27M | $9.02M | $9.70M | $8.83M | -$1.02M | -$17.35M | $4.18M |
| Investing cash flow | -$75.65M | -$358.30M | $38.03M | $2.78M | -$23.00M | -$983,000 | -$55.36M | -$5.03M |
| Financing cash flow | -$9.42M | -$20.88M | -$18.27M | -$7.42M | -$1.87M | -$7.69M | -$2.93M | -$313,000 |
| Depreciation & amortization | $359,000 | $379,000 | $3.73M | $3.66M | $354,000 | $867,000 | $2.84M | $2.52M |
| Stock-based compensation | $2.31M | $1.56M | $1.31M | $1.25M | $2.33M | $1.38M | $2.09M | $2.19M |
| Share buybacks | $9.41M | $16.13M | $16.73M | $4.27M | $1.86M | $3.61M | $0 | $0 |
Free plan shows the latest 8 periods; Pro shows all 35 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.